Publicações científicas

Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes

Iñarrairaegui M (1), Melero I (2), Sangro B (3).

(1) Liver Unit, Clínica Universidad de Navarra-IDISNA and CIBEREHD.
(2) Centro virtual de Investigacion Biomedica en red de Oncologia, CIBERONC.
(3) Liver Unit, Clínica Universidad de Navarra-IDISNA and CIBEREHD

Revisão:Clinical Cancer Research

Data: 14/Nov/2017

Imunologia e Imunoterapia [ES] Hepatologia

RESUMO

Treatment of patients with hepatocellular carcinoma in the advanced stage remains a great challenge, with very few drugs approved.

After decades of failures of immune therapies, immune checkpoint inhibitors have emerged as potentially effective treatments for patients with hepatocellular carcinoma in the advanced stage.

Immune checkpoints, including human cancer, cytotoxic T-lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), are surface proteins expressed in a variety of immune cells, and mostly provide immunosuppressive signals. Monoclonal antibodies able to block these molecules have shown antitumor activity against a wide spectrum of human cancers.

Clinical experience with checkpoint inhibitors in hepatocellular carcinoma includes early trials with the anti-CTLA-4 agent tremelimumab, and a large phase 2 trial with the anti-PD-1 agent nivolumab. The latter has shown strong activity particularly as second-line therapy, both in terms of tumor response and patient survival. At least three topics should be the focus of future research.

The search for activity in patients at less advanced stages, including the adjuvant treatment of patients with resectable or ablatable tumors. The enhanced efficacy of combination therapies, including particularly the combination with those targeted and locoregional therapies that may have a synergistic effect or act upon mechanisms of primary or acquired resistance to checkpoint inhibitors.

And the identification of clinical features and serum or tissue biomarkers that would allow a better patient selection for individual treatments. Hopefully, ongoing trials will help design better treatments in the next future.

CITAÇÃO DO ARTIGO  Clin Cancer Res. 2017 Nov 14. pii: clincanres.0289.2017. doi: 10.1158/1078-0432.CCR-17-0289

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra